Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine TumorsJennifer A. Chan, Matthew H. Kulke, Lawrence S. Blaszkowsky et al.|Journal of Clinical Oncology|2012Cited by 301
Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine TumorsJosefine Kjaer, Peter Stålberg, Thomas E. Clancy et al.|Annals of Surgery Open|2022Cited by 10
Abstract B004: EMT-associated integrin signaling drives resistance to RAS-GTP inhibition in pancreatic cancerJoshua H. Choe, Andrew J. Aguirre, Julien Dilly et al.|Cancer Research|2025Cited by 0